Table 1.
Details of included studies
| Trial ID | Sponsor | Drug | Comparison | Phase | Total participants | Age eligibility | N (%) aged ≥ 65 | Mean (SD) age | N (%) female |
|---|---|---|---|---|---|---|---|---|---|
| T2DM | |||||||||
| NCT01106625 | Janssen | Canagliflozin | Placebo | 3 | 469 | 18–80 years | 84 (17%) | 56.7 (9.3) | 230 (40%) |
| NCT01106677 | Janssen | Canagliflozin | Placebo | 3 | 1284 | 18–80 years | 206 (16%) | 55.4 (9.4) | 679 (53%) |
| NCT00734474 | Lilly | Dulaglutide | Sitagliptin, Placebo/Sitagliptin | 3 | 1202 | 18–75 years | 364 (30%) | 54.1 (9.9) | 643 (54%) |
| NCT01064687 | Lilly | Dulaglutide | Exenatide, Placebo | 3 | 978 | ≥ 18 years | 197 (20%) | 55.7 (9.8) | 406 (42%) |
| NCT01075282 | Lilly | Dulaglutide | Insulin | 3 | 810 | ≥ 18 years | 188 (23%) | 56.7 (9.5) | 393 (49%) |
| NCT01191268 | Lilly | Dulaglutide | Insulin | 3 | 884 | ≥ 18 years | 280 (32%) | 59.3 (9.2) | 411 (57%) |
| NCT01624259 | Lilly | Dulaglutide | Liraglutide | 3 | 599 | ≥ 18 years | 138 (23%) | 56.7 (9.3) | 312 (52%) |
| RA | |||||||||
| NCT00236028 | Janssen | Infliximab | Methotrexate | 3 | 1036 | 18–75 years | 127 (12%) | 50 (12.6) | 733 |
| NCT00264537 | Janssen | Golimumab | Placebo | 3 | 637 | ≥ 18 years | 52 (8%) | 49.5 (12.2) | 528 (83%) |
| NCT00264550 | Janssen | Golimumab | Placebo | 3 | 444 | ≥ 18 years | 38 (9%) | 50.4 (11.3) | 358 (81%) |
| NCT00361335 | Janssen | Golimumab | Placebo | 3 | 643 | ≥ 18 years | 46 (7%) | 49.4 (11.7) | 517 (18%) |
| NCT00106535 | Roche | Tocilizumab | Placebo | 3 | 1196 | ≥ 18 years | 173 (14%) | 52.0 (12.2) | 989 (83%) |
| NCT01119859 | Roche | Tocilizumab | Adalimumab | 4 | 326 | ≥ 18 years | 75 (23%) | 53.9 (12.7) | 262 (81%) |
| NCT01007435 | Roche | Tocilizumab | Placebo | 3 | 1162 | ≥ 18 years | 180 (15%) | 50.1 (13.5) | 904 (78%) |
| NCT01232569 | Roche | Tocilizumab | Placebo | 3 | 656 | ≥ 18 years | 81 (12%) | 52.1 (11.5) | 555 (85%) |
| COPD | |||||||||
| NCT01316913 | GSK | Umeclidinium bromide | Tiotropium | 3 | 872 | ≥ 40 years | 455 (52%) | 64.6 (8.4) | 280 (32%) |
| NCT01316900 | GSK | Umeclidinium bromide | Tiotropium | 3 | 846 | ≥ 40 years | 364 (43%) | 62.9 (9.0) | 261 (31%) |
| NCT01957163 | GSK | Umeclidinium bromide | Fluticasone, Placebo | 3 | 619 | ≥ 40 years | 299 (48%) | 64.4 (8.1) | 212 (32%) |
| NCT02119286 | GSK | Umeclidinium bromide | Fluticasone, Placebo | 3 | 620 | ≥ 40 years | 270 (44%) | 62.9 (8.2) | 228 (37%) |